Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for investigational convalescent plasma for the treatment of Covid-19 in hospitalized patients as part of the agency’s ongoing efforts to fight Covid-19. Based on scientific evidence available, the FDA concluded, as outlined in its decision memorandum, this product may be effective in treating Covid-19 and that the known and potential benefits of the product outweigh the known and potential risks of the product. U.S. Food and Drug Administration reported this on the website.
As it is reported, today’s action follows the FDA’s extensive review of the science and data generated over the past several months stemming from efforts to facilitate emergency access to convalescent plasma for patients as clinical trials to definitively demonstrate safety and efficacy remain ongoing.
"The EUA authorizes the distribution of Covid-19 convalescent plasma in the U.S. and its administration by health care providers, as appropriate, to treat suspected or laboratory-confirmed Covid-19 in hospitalized patients with Covid-19," the message says.
“The FDA’s emergency authorization for convalescent plasma is a milestone achievement in President Trump’s efforts to save lives from Covid-19,” said Secretary Azar. “The Trump Administration recognized the potential of convalescent plasma early on. Months ago, the FDA, BARDA, and private partners began work on making this product available across the country while continuing to evaluate data through clinical trials. Our work on convalescent plasma has delivered broader access to the product than is available in any other country and reached more than 70,000 American patients so far. We are deeply grateful to Americans who have already donated and encourage individuals who have recovered from Covid-19 to consider donating convalescent plasma,” Alex Azar, Health and Human Services Secretary said.